Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT) a prospective, open-label, randomized study

David E. Griffith, Gina Eagle, Rachel Thomson, Timothy R. Aksamit, Naoki Hasegawa, Kozo Morimoto, Doreen J. Addrizzo-Harris, Anne E. O'Donnell, Theodore K. Marras, Patrick A. Flume, Michael R. Loebinger, Lucy Morgan, Luigi R. Codecasa, Adam T. Hill, Stephen J. Ruoss, Jae Joon Yim, Felix C. Ringshausen, Stephen K. Field, Julie V. Philley, Richard J. WallaceJakko Van Ingen, Chris Coulter, James Nezamis, Kevin L. Winthrop

Research output: Contribution to journal › Article › peer-review

206 Scopus citations

Fingerprint

Dive into the research topics of 'Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT) a prospective, open-label, randomized study'. Together they form a unique fingerprint.

Medicine & Life Sciences